Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Summary

Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug/mL.

Timeline

Start

2023-01-11

Primary completion

2028-08-31

Completion

2028-08-31

Drugs

Indications